You can buy or sell NVLN and other stocks, options, ETFs, and crypto commission-free!
Novelion Therapeutics, Inc. engages in the development and commercialization of pharmaceuitical products. It focuses in providing new standards of care for individuals living with rare diseases. Read More The company was founded on February 3, 1981 and is headquartered in Vancouver, Canada.
Vancouver, British Columbia
52 Week High
52 Week Low
Yahoo FinanceMay 7
Novelion Therapeutics Reports First Quarter 2019 Financial Results
Company reiterates 2019 guidance of total net revenues between $160.0 and $175.0 million, including approximately $30.0 million of licensing revenues VANCOUVER, British Columbia, and CAMBRIDGE, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases (“Novelion” or the “Company”), today reported financial results for the first quarter ended March 31, 2019. Novelio...
$0.15 per share
$0.10 per share